Not recruiting

Study on the Effectiveness of Bevacizumab and Ranibizumab in Treating Age-Related Macular Degeneration in Patients with Genetic Variations

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of two treatments, Ranibizumab and Bevacizumab, for patients with Age-Related Macular Degeneration (AMD). AMD is a common eye condition that can lead to vision loss in older adults. The purpose of the study is to determine if Bevacizumab is as effective as Ranibizumab after one year of treatment for patients with AMD. Additionally, the study will explore how genetic differences, known as polymorphisms, might influence how patients respond to these treatments.

Participants in the study will receive either Ranibizumab or Bevacizumab through an injection into the eye, a method known as intravitreal use. The study will last for about a year, during which time participants will have regular check-ups to monitor their vision and overall health. Saliva samples will be collected to study genetic factors that might affect treatment response. This involves looking at specific genes that could play a role in how well the treatments work for different individuals.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment is being given to ensure unbiased results. By the end of the study, researchers hope to better understand the effectiveness of these treatments and the role of genetic factors in treating Age-Related Macular Degeneration.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, you will be informed about the purpose and procedures involved. You will be asked to provide consent to participate in the trial.
Step 2
Initial assessment
An initial assessment will be conducted to confirm your eligibility. This includes a review of your medical history and a detailed eye examination to ensure you meet the criteria for participation.
Step 3
Treatment assignment
You will be randomly assigned to receive either bevacizumab or ranibizumab. Both medications are administered through an injection into the eye, known as intravitreal use.
Step 4
Treatment administration
The treatment involves regular injections. The frequency and dosage will be determined by the study protocol and your healthcare provider. This will continue for a duration of one year.
Step 5
Regular follow-up visits
You will have regular follow-up visits to monitor your response to the treatment. These visits will include eye examinations and assessments of your visual acuity, which is a measure of how well you can see.
Step 6
Genetic testing
A saliva sample will be collected to study genetic factors that may influence your response to the treatment. This involves using a swab to collect cells from the inside of your mouth.
Step 7
Final evaluation
At the end of the one-year treatment period, a final evaluation will be conducted. This will include a comprehensive eye examination and a review of your overall health and response to the treatment.

Who can join the trial?

4 criteria

Patients must be diagnosed with neovascular Age-related Macular Degeneration (a condition affecting the eyes).
Patients must be 50 years or older.
Patients must have a recommendation from an eye doctor (ophthalmologist) to receive treatment with an anti-VEGF agent (a type of medication used to treat eye conditions).
Patients must not have had any previous treatment in the eye being studied, specifically no prior anti-VEGF treatment for Age-related Macular Degeneration.

Who cannot join the trial?

10 criteria

Patients who have any other eye diseases that could affect the study results.
Patients who have had eye surgery in the last three months.
Patients who are allergic to the study drugs or any of their ingredients.
Patients who are currently participating in another clinical trial.
Patients who have uncontrolled high blood pressure.
Patients who have had a heart attack or stroke in the last six months.
Patients who are pregnant or breastfeeding.
Patients who have a history of drug or alcohol abuse.
Patients who have any serious medical conditions that could interfere with the study.
Patients who are unable to follow the study procedures or attend the required visits.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
Verified
Hospital Del Mar
Barcelona, Spain
Verified
Hospital Universitario De Canarias
La Laguna, Spain

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ranibizumab
is a medication used to treat a condition called Age-Associated Macular Degeneration (AMD), which affects the eyes and can lead to vision loss. It works by blocking a protein in the body that can cause abnormal blood vessels to grow in the eye, which can damage vision. In this clinical trial, Ranibizumab is being studied to see how effective it is in treating AMD and how genetic differences in patients might affect their response to the treatment.
Bevacizumab
is another medication used in the treatment of Age-Associated Macular Degeneration (AMD). Like Ranibizumab, it helps prevent the growth of abnormal blood vessels in the eye that can harm vision. This trial is comparing Bevacizumab to Ranibizumab to determine if it is equally effective in treating AMD over a one-year period. The study also looks at how genetic variations in patients might influence their response to Bevacizumab treatment.

What is already known about the treatment

Ranibizumab
Ranibizumab is administered as an injection directly into the eye, specifically targeting the area affected by Age-Associated Macular Degeneration (AMD). It is currently well-established in medical practice and literature as a treatment for AMD. The main therapeutic indication for Ranibizumab is to slow the progression of vision loss in patients with AMD. At the molecular level, it works by inhibiting a protein called VEGF, which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is classified as an anti-VEGF agent, which helps to reduce swelling and prevent further damage to the retina.
Bevacizumab
Bevacizumab is also administered as an injection into the eye for the treatment of Age-Associated Macular Degeneration (AMD). It is widely used in clinical settings and is being evaluated for its effectiveness compared to Ranibizumab. The primary therapeutic use of Bevacizumab is to manage AMD by preventing the growth of abnormal blood vessels in the eye. Its mechanism of action involves blocking the VEGF protein, similar to Ranibizumab, to reduce swelling and protect the retina. Bevacizumab is classified as an anti-VEGF medication, helping to maintain vision in patients with AMD.

Investigated diseases

Age-Associated Macular Degeneration – Age-Associated Macular Degeneration is a chronic eye condition that affects the macula, the central part of the retina responsible for sharp, straight-ahead vision. It typically progresses slowly and can lead to a gradual loss of central vision, making it difficult to read, drive, or recognize faces. The disease is characterized by the presence of drusen, which are yellow deposits under the retina, and can advance to more severe forms involving abnormal blood vessel growth or retinal atrophy. As the condition progresses, individuals may experience blurred or distorted vision, and in advanced stages, central vision may be significantly impaired. The progression of the disease varies among individuals, with some experiencing a slow decline in vision, while others may have a more rapid deterioration.